SCHEMBL2560339

SCHEMBL2560339

c1ccc2cc(-c3nnc4n3CCNC4)ncc2c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 2/20 0.50
CYP1A2 P05177 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HTR2A P28223 3/20 0.40
HTR2C P28335 3/20 0.40
MIF P14174 1/20 0.37
HTR3A P46098 1/20 0.37
MAP3K5 Q99683 1/20 0.37
NPC1 O15118 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
BTK Q06187 1/20 0.36
MCHR1 Q99705 1/20 0.36
GSK3B P49841 2/20 0.35
DYRK1A Q13627 2/20 0.35
WNT1 P04628 1/20 0.35
CYP2A6 P11509 1/20 0.35
RAB9A P51151 1/20 0.35
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL14634750 0.99 TACR3 (0.49) TACR3CYP1A2KDM4EHTR2AHTR2C
SCHEMBL106779 0.79 TACR3 (0.52) TACR3CYP1A2NPC1
Hydrochloric Acid SCHEMBL2565514 0.78 TACR3 (0.51) TACR3CYP1A2NPC1
Hydrochloric Acid SCHEMBL2565311 0.76 TACR3 (0.48) TACR3CYP1A2KDM4EHTR2AHTR2C
Hydrochloric Acid SCHEMBL2560610 0.76 P2RX7 (0.40) TACR3HTR2AHTR2C
SCHEMBL706557 0.75 HPGD (0.56) TACR3KDM4EHTR2AHTR2CGSK3B
SCHEMBL16291433 0.74 TACR3 (0.59) TACR3CYP1A2MIF
Hydrochloric Acid SCHEMBL2562060 0.74 PDCD1 (0.44) TACR3HTR2AHTR2CMAP3K5GSK3B
Hydrochloric Acid SCHEMBL2562382 0.73 TACR3 (0.46) TACR3CYP1A2HTR2AHTR2CHTR3A
SCHEMBL16027876 0.72 P2RX7 (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2552920-A1 NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS Euroscreen S.A. (BE) 2013-02-06 EP disclosed
WO-2011121137-A1 NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS EUROSCREEN S.A. (BE) 2011-10-06 WO disclosed